In accordance with the provisions of Article 6(3) of the Directive the Commission confirmed in its Decision 98/ 242/EC fn that the dossier submitted for azafenidin could be considered as satisfying, in principle, the data and information requirements of Annex II and for a plant protection product containing this active substance, of Annex III to the Directive.

If, after that examination, the Directorate-General or department holding the document considers that access to it must be refused under one of the exceptions provided for by Article 4 of Regulation (EC) No 1049/2001, the negative answer shall be sent to the applicant without consultation of the third-party author.

For patients with renal impairment the following dosage adjustments should be considered:

An additional antibiotic treatment should be considered for safety reasons.

The use of Optisulin may be considered in pregnancy, if necessary.

how to determine whether a series of transactions is linked and should be accounted for as one transaction;

The treatment should be reconsidered if at 5 days no improvement in the clinical condition is observed.

Furthermore a reduction of dosage or termination of therapy may be considered.

The need for continued treatment should be assessed by a doctor every six months.

Your doctor needs to assess the benefits and potential risks of giving you the vaccine if you are below the age of 18 years.

Administration of protamine should be considered if heparin has been administered within 4 hours before the onset of bleeding.

The level and nature of acceptable contaminants should be judged from a risk assessment point of view, by the competent authority.

Your doctor needs to assess the benefits and potential risks of giving you the vaccine if you are pregnant.

In case the clinical diagnosis of compartment syndrome is made the following treatment should be considered: 1.

2 If the recommended dose is not tolerated by the subject, treatment with a lower dose can be considered.

Your doctor needs to assess the benefits and potential risks of giving you the vaccine if you are pregnant or breast- feeding.

If in cases of deep pyoderma, sufficient improvement is not seen after a treatment course of 21 days, it is recommended that the treatment is reconsidered.

Whereas projects belonging to certain types have significant effects on the environment and these projects must as a rule be subject to systematic assessment;

Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.

Therefore the physician should determine if the benefit of treatment outweighs the risk (see sections 4.2 and 4.3).

The notified body must assess the quality assurance system to determine whether it satisfies the requirements referred to in Section 3.2.

You are responsible to decide if you are able to drive a motor vehicle or perform other tasks that require increased concentration.

It should be determined whether this restriction of their business autonomy is sufficiently appreciable to be caught by Article 85.

Healthcare providers need to assess the benefits and potential risks of administering the vaccine to pregnant women taking into consideration official recommendations.

In accordance with national recommendations, your doctor might consider that you need supplementary measures to prevent infection.

In particular, there is a need to rethink the arrangements for applying the exception from the prohibition on agreements, which restrict competition, laid down in Article 81(3) of the Treaty.

The potential benefits to the mother and risks to the infant should be considered before administering Prepandrix during lactation.

If there is no response within 6 months, doctors should consider the benefits and risks of continuing treatment, and consider alternative treatments.

- Recent gastrointestinal or genitourinary bleeding (within the past 10 days)

Additional supplementation with vitamin D should be considered on an individual basis taking into account any vitamin D intake from vitamins and dietary supplements.

If a gastrointestinal complication is suspected during treatment, piroxicam should be discontinued immediately and additional clinical evaluation and treatment should be considered.” … [ ]…

The notified body must assess the changes proposed and verify whether after these changes the quality system still meets the requirements referred to in section 3.2.

However, you should take into account the state of your health and the possible side effects of Kivexa before considering driving or using machines.

Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.

In the case of treatment failure associated with S. aureus, the presence of strains possessing additional virulence factors (such as Panton-Valentine Leukocidin) should be considered.

However, you should take into account the state of your health and the possible side effects of Trizivir before considering driving or using machines.

If an elevated or rising potassium level is observed then consideration should be given to ceasing NeoRecormon administration until the level has been corrected.

If no response to treatment is obtained the diagnosis should be reconsidered in order to investigate other causes for the incontinence such as neurological disorders, bladder neoplasia, etc.

Previously unknown medical dispositions, which are discovered immediately before departure and which may affect the enforcement of the removal, should be assessed with the responsible authorities;

The notified body must assess the changes proposed and decide whether the altered quality system will still satisfy the requirements referred to in 3.2 or whether a reassessment is required.

The next step would be to review the strategy behind the selection criteria and to decide what criteria are to be applied to the selection procedure of the new plot.

A decision on whether to continue or discontinue breast-feeding or to continue or discontinue therapy with MIRCERA should be made taking into account the benefit of breast-feeding to the child and the benefit of MIRCERA therapy to the woman.

The notified body must assess the changes proposed and decide whether the altered quality system will still satisfy the requirements referred to in 3.2 or whether reassessment in required.

Metabolite 14-OH clarithromycin AUC ↑ 1.42 (1.16-1.73) Metabolite 14-OH clarithromycin Cmin ↔ 0 (0.68-1.49) Metabolite 14-OH clarithromycin Cmax ↑ 1.47 (1.21-1.80)

Before the end of the trial period, the Commission must carry out a thorough review of the utility and scope of the framework, which must inter alia consider the question of whether it should be renewed, revised or abolished.

all relevant information on the lifts, in particular information which makes for an understanding of the relationship between the design and operation of the lift and enables conformity with the requirements of the Directive to be assessed,

Moreover, these factors have to be judged by reference to the structure and particular characteristics of the market in which the competition concerns arise, including of course the position of the parties and other players on the market.

Whereas projects of other types may not have significant effects on the environment in every case and whereas these projects should be assessed where the Member States consider that their characteristics so require;

Reviews shall assess the continued existence of subsidies or unfair pricing, and/or injury caused thereby, together with a new determination as to whether the Community interest calls for continued intervention.

The possible need for combination therapy with gastro-protective agents (e. g. misoprostol or proton pump inhibitors) should be carefully considered. (see section 4.2).